{"doi":"10.1111/pde.15792","title":"Cutaneous Toxicities of <scp>MEK</scp> Inhibitor Use in Children: A Comparison of Binimetinib and Selumetinib","abstract":"<jats:title>ABSTRACT</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Binimetinib and selumetinib are two mitogen‐activated protein kinase kinase (MEK) inhibitors used to treat low‐grade gliomas and plexiform neurofibromas. Cutaneous toxicities are commonly associated with MEK inhibitors; however, limited studies have examined cutaneous effects in a pediatric population or whether toxicities vary between MEK inhibitors.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We conducted an IRB‐approved, single‐center, retrospective review of pediatric neuro‐oncology patients on binimetinib or selumetinib who presented to NYU from April 2016 through July 2022.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Forty‐six children met inclusion criteria (23 females, 23 males) with a mean age of 11.7 years. Thirty‐three were treated with binimetinib and 13 with selumetinib. Dermatologic adverse events were encountered in 97.8% of the cohort, and the most common were acneiform eruption (63.0%), paronychia (58.7%), and xerosis (54.3%). Children 12 years and older were more likely to have acneiform eruption (<jats:italic>p</jats:italic> &lt; 0.001) and seborrheic dermatitis (<jats:italic>p</jats:italic> &lt; 0.001), while children under 12 were more likely to have xerosis (<jats:italic>p</jats:italic> = 0.037). The incidence of cutaneous adverse events was significantly different between MEK inhibitors for folliculitis and hair pigment dilution (39.4% binimetinib, 0% selumetinib, <jats:italic>p</jats:italic> = 0.009). Significantly, more patients required MEK inhibitor dose reduction/hold on binimetinib (87.9%) than selumetinib (46.2%) (<jats:italic>p</jats:italic> = 0.006). Severity of cutaneous disease was not associated with tumor response.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Our study confirms dermatologic adverse events are common in children on MEK inhibitors. Age appears to be associated with increased likelihood of certain cutaneous reactions. Overall, the selumetinib patients in our cohort presented with less severe adverse events and decreased risk of MEK inhibitor dose reduction/hold. Our results will aid clinicians in providing appropriate counseling, treatments, and improved preventive care.</jats:p></jats:sec>","journal":"Pediatric Dermatology","year":2025,"id":603304,"datarank":0.29188652235829704,"base_score":1.9459101490553132,"endowment":1.9459101490553132,"self_citation_contribution":0.29188652235829704,"citation_network_contribution":0.0,"self_endowment_contribution":0.29188652235829704,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":6,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1207501,"name":"Lu Yin","orcid":"0000-0002-4978-8439","position":1,"is_corresponding":false},{"id":711310,"name":"Trevor K. Young","orcid":"0000-0003-0215-9886","position":2,"is_corresponding":false},{"id":1472447,"name":"Steven Friedman","orcid":null,"position":3,"is_corresponding":false},{"id":801013,"name":"Soutrik Mandal","orcid":"0000-0002-0625-8999","position":4,"is_corresponding":false},{"id":663217,"name":"Devorah Segal","orcid":"0000-0002-9740-1286","position":5,"is_corresponding":false},{"id":1547654,"name":"Kaleb H. Yohay","orcid":null,"position":6,"is_corresponding":false},{"id":1547659,"name":"Nikita R. Lakdawala","orcid":null,"position":7,"is_corresponding":false},{"id":929524,"name":"Vikash S. Oza","orcid":"0000-0002-9102-0773","position":8,"is_corresponding":false},{"id":419783,"name":"Carli D. Needle","orcid":"0009-0002-9768-3831","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Cutaneous Toxicities of <scp>MEK</scp> Inhibitor Use in Children: A Comparison of Binimetinib and Selumetinib","abstract":"<jats:title>ABSTRACT</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Binimetinib and selumetinib are two mitogen‐activated protein kinase kinase (MEK) inhibitors used to treat low‐grade gliomas and plexiform neurofibromas. Cutaneous toxicities are commonly associated with MEK inhibitors; however, limited studies have examined cutaneous effects in a pediatric population or whether toxicities vary between MEK inhibitors.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We conducted an IRB‐approved, single‐center, retrospective review of pediatric neuro‐oncology patients on binimetinib or selumetinib who presented to NYU from April 2016 through July 2022.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Forty‐six children met inclusion criteria (23 females, 23 males) with a mean age of 11.7 years. Thirty‐three were treated with binimetinib and 13 with selumetinib. Dermatologic adverse events were encountered in 97.8% of the cohort, and the most common were acneiform eruption (63.0%), paronychia (58.7%), and xerosis (54.3%). Children 12 years and older were more likely to have acneiform eruption (<jats:italic>p</jats:italic> &lt; 0.001) and seborrheic dermatitis (<jats:italic>p</jats:italic> &lt; 0.001), while children under 12 were more likely to have xerosis (<jats:italic>p</jats:italic> = 0.037). The incidence of cutaneous adverse events was significantly different between MEK inhibitors for folliculitis and hair pigment dilution (39.4% binimetinib, 0% selumetinib, <jats:italic>p</jats:italic> = 0.009). Significantly, more patients required MEK inhibitor dose reduction/hold on binimetinib (87.9%) than selumetinib (46.2%) (<jats:italic>p</jats:italic> = 0.006). Severity of cutaneous disease was not associated with tumor response.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Our study confirms dermatologic adverse events are common in children on MEK inhibitors. Age appears to be associated with increased likelihood of certain cutaneous reactions. Overall, the selumetinib patients in our cohort presented with less severe adverse events and decreased risk of MEK inhibitor dose reduction/hold. Our results will aid clinicians in providing appropriate counseling, treatments, and improved preventive care.</jats:p></jats:sec>","is_dataset_classified":null,"base_score":1.9459101490553132,"endowment":1.9459101490553132,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"39511793","pmcid":null,"openalex_id":"https://openalex.org/W4404196053","authors":[],"funders":[],"total_grants":0,"fwci":0.9764,"citation_percentile":0.74561728,"influential_citations":0,"citation_trend":[{"year":2025,"count":2},{"year":2026,"count":4}],"oa_status":"bronze","license":"http://onlinelibrary.wiley.com/termsAndConditions#vor","oa_locations":[{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/pde.15792","host_type":"journal"},{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/pde.15792","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/pde.15792","host_type":"publisher"},{"url":"https://doi.org/10.1111/pde.15792","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/39511793","host_type":"repository"}],"fields_of_study":["Melanoma and MAPK Pathways","Neurofibromatosis and Schwannoma Cases","Glioma Diagnosis and Treatment","Humans","Child","Male","Female","Benzimidazoles","Retrospective Studies","Adolescent","Child, Preschool","Drug Eruptions","Protein Kinase Inhibitors","Mitogen-Activated Protein Kinase Kinases","Glioma","Neurofibroma, Plexiform"],"mesh_terms":["Adolescent","Benzimidazoles","Child","Child, Preschool","Drug Eruptions","Female","Glioma","Humans","Male","Retrospective Studies","Neurofibroma, Plexiform","Mitogen-Activated Protein Kinase Kinases","Protein Kinase Inhibitors"],"keywords":["Selumetinib","Medicine","MEK inhibitor","Dermatology","Pharmacology","MAPK/ERK pathway","Kinase","Genetics","Cancer","ACNE","Oncology","Mek Inhibitors","Drug Reaction","Pediatric Dermatology"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-29T21:33:56.009849Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}